Stuart T. Haines: Pharmacist-Led Warfarin Management Improves Therapeutic Control in HeartMate 3 LVAD Patients
Stuart T. Haines, Editor-in-Chief JACCP, Professor and Director of Professional Development at University of Mississippi School of Pharmacy, shared on LinkedIn about a recent article by Bailey M. Colvin et al, published in Journal of the American College of Clinical Pharmacy, adding:
”The evidence for pharmacist-managed anticoagulation in patients just got a lot stronger.
A new study published in the Journal of the American College of Clinical Pharmacy – the largest multicenter cohort focused exclusively on LVAD patients – found that pharmacist-led warfarin management achieved a mean time-in-therapeutic range (TTR) of 65.6% versus 45.8% in patients managed by nonpharmacist clinicians.
That near-20-point advantage held after multivariable adjustment and came with no significant increase in clinically significant bleeding.
This fills a real evidence gap.
Prior studies in LVAD populations were small, single-center, and often included older device generations.
This study’s multicenter design and exclusive focus on the HeartMate 3 LVAD reflect current clinical practice – and the results strongly support the key role that pharmacists can play in the care of this very complex patient population under collaborative practice agreements.
Congratulations to authors Bailey Colvin, PharmD, BCCP, Lauren Kunkel, PharmD, BCCP, and the entire investigative team for this important contribution to the literature!”
Title: Comparing Pharmacist-Managed Warfarin Versus Usual Care in HeartMate 3 Patients: A Multicenter Retrospective Observational Study
Authors: Bailey M. Colvin, Lauren Kunkel, Abby Bauer, April S. Britt, Christine Cadiz, Paige Carrigan, Teresa Chu, Kathleen Faulkenberg, Corinn Floyd, Ian Hollis, Mackenzie Payne, Amanda Prosenjak, Sijin Wen, Jordan C. Wilkie, Meiling Zheng, Kazuhiko Kido
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis